Skip to main content

Table 4 Prognostic implications of switches of the antifibrotics in patients with IPF by univariate and multivariate Cox-proportion analyses

From: Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study

Predictor

HR

95% CI

p value

 

HR

95% CI

p value

Univariate analysis

Multivariate analysis 1

Age, year

1.024

1.000–1.050

0.0481

Age, year

1.003

0.978–1.029

0.8402

Gender, male

1.054

0.652–1.624

0.8218

Gender, male

1.455

0.905–2.438

0.1365

History of AE, yes

2.413

1.518–3.677

< 0.0001

History of AE, yes

1.062

0.602–1.777

0.8268

Pirfenidone

1.002

0.694–1.425

0.9892

BMI, per 1 kg/m2 increase

0.956

0.904–1.009

0.1051

Period: Diagnosis-administration

1.001

0.996–1.005

0.7124

FVC, per 1% increase

0.978

0.967–0.989

0.0001

BMI, per 1 kg/m2 increase

0.905

0.860–0.953

0.0001

LTOT, yes

1.774

1.205–2.590

0.0032

FVC,per 1% increase

0.970

0.959–0.980

< 0.0001

Patients with IPF who switched antifibrotics

0.392

0.221–0.656

0.0007

FEV1, per 1% increase

0.989

0.979–0.999

0.0261

Multivariate analysis 2

FEV1/FVC, per 1% increase

1.061

1.038–1.089

< 0.0001

Age, year

1.005

0.979–1.032

0.7131

DLCO, per 1% increase

0.974

0.962–0.986

< 0.0001

Gender, male

1.536

0.940–2.618

0.0992

TP, per 1 g/dl increase

0.978

0.763–1.271

0.8647

History of AE, yes

1.214

0.684–2.267

0.5247

Alb, per 1 g/dl increase

0.601

0.411–0.896

0.0105

BMI, per 1 kg/m2 increase

0.940

0.883–0.997

0.0440

KL-6, per 1 U/ml increase

1.000

1.000–1.000

0.0003

FVC, per 1% increase

0.980

0.968–0.991

0.0007

SP-D, per 1 ng/ml increase

1.001

1.000–1.002

0.0510

KL-6, per 1 U/ml increase

1.000

1.000–1.000

0.0217

LTOT, yes

2.575

1.847–3.574

< 0.0001

LTOT, yes

1.660

1.103–2.468

0.0135

Patients with IPF who switched antifibrotics

0.318

0.182–0.506

< 0.0001

Patients with IPF who switched antifibrotics s

0.374

0.206–0.638

0.0006

Switching antifibrotics (time dependent covariate)

0.895

0.517–1.550

0.692

    
  1. AE acute exacerbation, BMI body mass index, FVC forced vital capacity, FEV1.0 forced expiratory volume in 1.0 s, DLCO diffuse capacity of the lung for carbon monoxide, LTOT long-term oxygen therapy
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us